Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Psychiatr Pract ; 21(6): 449-57, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26554329

RESUMO

We report the case of a woman with long-standing refractory depression and psychotic features who was eventually diagnosed with Cushing disease. After surgical treatment of a pituitary adenoma, she experienced gradual psychiatric recovery and was eventually able to discontinue all psychotropic medication. We review the psychiatric components of Cushing disease, implications of psychiatric illnesses for the treatment and prognosis of Cushing disease, and potential pathophysiological mechanisms linking glucocorticoid excess to psychiatric illness.


Assuntos
Adenoma/cirurgia , Transtornos Psicóticos Afetivos , Hipofisectomia/métodos , Hipersecreção Hipofisária de ACTH , Neoplasias Hipofisárias/cirurgia , Transtornos Psicóticos Afetivos/diagnóstico , Transtornos Psicóticos Afetivos/etiologia , Transtornos Psicóticos Afetivos/fisiopatologia , Transtornos Psicóticos Afetivos/terapia , Feminino , Humanos , Pessoa de Meia-Idade , Hipersecreção Hipofisária de ACTH/complicações , Hipersecreção Hipofisária de ACTH/diagnóstico , Hipersecreção Hipofisária de ACTH/psicologia , Hipersecreção Hipofisária de ACTH/cirurgia , Escalas de Graduação Psiquiátrica , Resultado do Tratamento
2.
J Clin Psychiatry ; 72(9): 1222-8, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21733489

RESUMO

OBJECTIVE: The lack of generally accepted diagnostic criteria for neuroleptic malignant syndrome (NMS) impedes research and clinical management of patients receiving antipsychotic medications. The purpose of this study was to develop NMS diagnostic criteria reflecting a broad consensus among clinical knowledge experts, represented by an international multispecialty physician panel. PARTICIPANTS: Eleven psychiatrists, 2 neurologists, 2 anesthesiologists, and 2 emergency medicine specialists participated in a formal Delphi consensus procedure. EVIDENCE: A core bibliography consisting of 12 prominent, current reviews of the NMS literature was identified by an objective, comprehensive electronic search strategy. Each panel member was given a copy of these references and asked to examine them before commencing the survey process. CONSENSUS PROCESS: After reviewing the core bibliography, panel members were asked to list any clinical signs or symptoms or diagnostic studies that they believed, on the basis of their knowledge and clinical experience, were useful in making a diagnosis of NMS. In subsequent survey rounds, panel members assigned priority points to these items, and items that failed to receive a minimum priority score were eliminated from the next round. Information about individual panel member responses was fed back to the group anonymously in the form of the group median or mean and the number of members who had ranked or scored each survey item. The a priori consensus endpoint was defined operationally as a change of 10% or less in the mean priority score for any individual item, and an average absolute value change of 5% or less across all items, between consecutive rounds. The survey was conducted from January 2009 through September 2009. RESULTS: Consensus was reached on the fifth round regarding the following criteria: recent dopamine antagonist exposure, or dopamine agonist withdrawal; hyperthermia; rigidity; mental status alteration; creatine kinase elevation; sympathetic nervous system lability; tachycardia plus tachypnea; and a negative work-up for other causes. The panel also reached a consensus on the relative importance of these criteria and on the following critical values for quantitative criteria: hyperthermia, > 100.4°F or > 38.0°C on at least 2 occasions; creatine kinase elevation, at least 4 times the upper limit of normal; blood pressure elevation, ≥ 25% above baseline; blood pressure fluctuation, ≥ 20 mm Hg (diastolic) or ≥ 25 mm Hg (systolic) change within 24 hours; tachycardia, ≥ 25% above baseline; and tachypnea, ≥ 50% above baseline. CONCLUSIONS: These diagnostic criteria significantly advance the field because they represent the consensus of an international multispecialty expert panel, include critical values, provide guidance regarding the relative importance of individual elements, and are less influenced by particular theoretical biases than most previously published criteria. They require validation before being applied in clinical settings.


Assuntos
Síndrome Maligna Neuroléptica/diagnóstico , Guias de Prática Clínica como Assunto/normas , Consenso , Coleta de Dados , Técnica Delphi , Humanos , Estudos Interdisciplinares
4.
Schizophr Bull ; 36(2): 239-42, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19969591

RESUMO

Psychiatric diagnoses are currently categorized on a syndromic basis. The syndrome of catatonia, however, remains in a diagnostic limbo, acknowledged predominantly as a subtype of schizophrenia. Yet, catatonia is present in about 10% of acutely ill psychiatry patients, only a minority of whom have schizophrenia. Among those with comorbid affective disorders, who comprise the largest subgroup of catatonic patients, the catatonic signs typically resolve dramatically and completely with benzodiazepine therapy. Those with schizophrenia respond less reliably, suggesting that the underlying processes causing the catatonia may be different in this group. The majority of patients with catatonia have concurrent psychosis. Failure to treat the catatonia before institution of antipsychotic medication may increase the risk of inducing neuroleptic malignant syndrome. At this point of time, the pathobiology of catatonia is unknown; the major reason for considering catatonia as a separate diagnostic entity would be to increase recognition of this eminently treatable neuropsychiatric syndrome.


Assuntos
Benzodiazepinas/uso terapêutico , Catatonia/tratamento farmacológico , Esquizofrenia Catatônica/tratamento farmacológico , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Benzodiazepinas/efeitos adversos , Catatonia/diagnóstico , Catatonia/psicologia , Terapia Combinada , Quimioterapia Combinada , Eletroconvulsoterapia , Humanos , Síndrome Maligna Neuroléptica/prevenção & controle , Esquizofrenia Catatônica/diagnóstico , Esquizofrenia Catatônica/psicologia , Síndrome
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA